Christopher Stevo | SVP & Chief IR Officer |
Albert Bourla | Chairman & CEO |
Mikael Dolsten | Chief Scientific Officer & President, Worldwide Research, Development & Medical |
Frank D'Amelio | CFO |
Aamir Malik | EVP & Chief Business Innovation Officer |
William Pao | EVP & Chief Development Officer |
Angela Hwang | Group President of Biopharmaceuticals Group |
Louise Chen | Cantor Fitzgerald & Co. |
Evan Seigerman | BMO Capital Markets |
Mohit Bansal | Wells Fargo Securities |
Terence Flynn | Morgan Stanley |
Stephen Scala | Cowen and Company |
Carter Gould | Barclays Bank |
Alexandria Hammond | Bank of America Merrill Lynch |
Timothy Anderson | Wolfe Research |
Robyn Karnauskas | Truist Securities |
Vamil Divan | Mizuho Securities |
Christopher Schott | JPMorgan Chase & Co. |
Kerry Holford | Berenberg |
Colin Bristow | UBS |
Andrew Baum | Citigroup |
Good day, everyone, and welcome to Pfizer's First Quarter 2022 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Chris Stevo, Senior Vice President and Chief Investor Relations Officer. Please go ahead, sir.
Thank you, operator.